Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0VHZVS
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
ADCT-211
|
|||||
| Synonyms |
ADCT211; ADCT 211
Click to Show/Hide
|
|||||
| Organization |
ADC Therapeutics SA
|
|||||
| Drug Status |
Clinical candidate
|
|||||
| Indication |
In total 2 Indication(s)
Glioblastoma [ICD11:2A00]
Clinical candidate
Melanoma [ICD11:2C30]
Clinical candidate
|
|||||
| Drug-to-Antibody Ratio |
1.8
|
|||||
| Antibody Name |
Anti-IL13RA2 mAb huCl47
|
Antibody Info | ||||
| Antigen Name |
Interleukin-13 receptor subunit alpha-2 (IL13RA2)
|
Antigen Info | ||||
| Payload Name |
SG2000
|
Payload Info | ||||
| Therapeutic Target |
Human Deoxyribonucleic acid (hDNA)
|
Target Info | ||||
| Linker Name |
Vali-Ala cleavable linker
|
Linker Info | ||||
| Conjugate Type |
Site-specifically conjugated using GlycoConnectTM technology to PL1801.
|
|||||
| Combination Type |
PL1801
|
|||||
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.